Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—an update

Q Mao, JD Unadkat - The AAPS journal, 2015 - Springer
The human breast cancer resistance protein (BCRP, gene symbol ABCG2) is an ATP-
binding cassette (ABC) efflux transporter. It was so named because it was initially cloned …

Membrane transporters in drug development

Nature reviews Drug discovery, 2010 - nature.com
Membrane transporters can be major determinants of the pharmacokinetic, safety and
efficacy profiles of drugs. This presents several key questions for drug development …

Transporters and drug-drug interactions: important determinants of drug disposition and effects

J König, F Müller, MF Fromm, MC Michel - Pharmacological reviews, 2013 - Elsevier
Uptake and efflux transporters determine plasma and tissue concentrations of a broad
variety of drugs. They are localized in organs such as small intestine, liver, and kidney …

Impact of OATP transporters on pharmacokinetics

A Kalliokoski, M Niemi - British journal of pharmacology, 2009 - Wiley Online Library
Membrane transporters are now recognized as important determinants of the
transmembrane passage of drugs. Organic anion transporting polypeptides (OATP) form a …

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

M Niemi, MK Pasanen, PJ Neuvonen, M Koulu - Pharmacological reviews, 2011 - Elsevier
The importance of membrane transporters for drug pharmacokinetics has been increasingly
recognized during the last decade. Organic anion transporting polypeptide 1B1 (OATP1B1) …

Drug interactions with lipid‐lowering drugs: mechanisms and clinical relevance

PJ Neuvonen, M Niemi… - Clinical Pharmacology & …, 2006 - Wiley Online Library
Lipid‐lowering drugs, especially 3‐hydroxy‐3‐methylglutaryl–coenzyme A inhibitors
(statins), are widely used in the treatment and prevention of atherosclerotic disease. The …

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics

RH Ho, RG Tirona, BF Leake, H Glaeser, W Lee… - Gastroenterology, 2006 - Elsevier
Background & Aims The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors, or statins, target liver HMG-CoA and are of proven benefit in the prevention of …

Clinical studies on drug–drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation

A Tornio, AM Filppula, M Niemi… - Clinical Pharmacology …, 2019 - Wiley Online Library
Many drug–drug interactions (DDI s) are based on alterations of the plasma concentrations
of a victim drug due to another drug causing inhibition and/or induction of the metabolism or …

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and …

Y Shitara, Y Sugiyama - Pharmacology & therapeutics, 2006 - Elsevier
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely
used for the treatment of hypercholesterolemia. Their efficacy in preventing cardiovascular …

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

MK Pasanen, M Neuvonen… - Pharmacogenetics …, 2006 - journals.lww.com
Methods Four healthy volunteers with the homozygous SLCO1B1 c. 521CC genotype, 12
with the heterozygous c. 521TC genotype and 16 with the homozygous c. 521TT genotype …